10 Best Generate Biomedicines Alternatives & Competitors (2026)

Schrödinger provides physics-based molecular simulation software used for drug discovery across pharma and biotech. Its platform excels at structure-based design and predictive modeling with broad small-molecule coverage. Unlike Nabla Bio's integrated generative antibody focus and owned wet-lab data engine, Schrödinger primarily licenses computational tools that customers combine with external experimental resources, resulting in different cost structures and validation workflows.

Recursion applies machine learning to large-scale cellular imaging for phenotypic drug discovery across many targets. Its strength lies in rapid hypothesis generation from millions of experiments, yet it remains primarily cell-phenotype driven rather than RNA-sequence or splicing focused like Serna Bio. Pricing is typically partnership-based; teams seeking explicit RNA modulation may find Recursion broader but less specialized for translation targets.

Insilico Medicine runs an end-to-end AI platform for target discovery through clinical candidate nomination, covering multiple disease areas. It has advanced several AI-designed molecules into human trials. Compared with Nabla Bio, Insilico offers wider therapeutic modality exploration and later-stage clinical momentum but maintains a less specialized emphasis on antibody developability testing at the scale Nabla Bio integrates internally.

Recursion applies machine learning to large-scale cellular imaging for phenotypic drug discovery across many targets. Its strength lies in rapid hypothesis generation from millions of experiments, yet it remains primarily cell-phenotype driven rather than RNA-sequence or splicing focused like Serna Bio. Pricing is typically partnership-based; teams seeking explicit RNA modulation may find Recursion broader but less specialized for translation targets.

Exscientia applies AI to precision design of small-molecule drugs and has multiple clinical-stage assets. Its platform emphasizes patient tissue data and automated design cycles. Relative to Nabla Bio's antibody-centric generative approach and fully owned dry/wet-lab stack, Exscientia focuses more on small molecules and has historically relied on partnered experimental validation rather than a single integrated engine.

Atomwise uses deep learning for structure-based small-molecule screening and design, serving multiple pharma partners. It provides large-scale virtual screening services. In contrast to Nabla Bio's de novo antibody generation paired with patient-relevant assays, Atomwise centers on small-molecule hit finding and typically operates without an in-house large-scale human biology testing infrastructure.

BenevolentAI applies machine learning to knowledge graphs and experimental data for target identification and molecule design, primarily in small molecules. Its approach differs from Nabla Bio by prioritizing disease mechanism mining over antibody-specific generative design and by relying more on partner labs for validation.

Relay integrates computational and experimental methods to drug dynamic proteins. Its motion-based approach improves on static structures, but remains protein-centric and does not replicate Serna Bio's focus on RNA modulation through AI-driven, unconstrained molecular design.

Absci combines generative AI with its proprietary high-throughput wet-lab platform to design and optimize antibodies and proteins. It offers both partnered programs and internal pipeline efforts. This creates closer operational similarity to Nabla Bio than pure software vendors, though Absci's scale and partnership terms differ in emphasis on manufacturing-ready cell-line integration.